Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
30.13
Dollar change
-1.61
Percentage change
-5.07
%
IndexRUT P/E- EPS (ttm)-3.48 Insider Own0.87% Shs Outstand11.76M Perf Week-9.16%
Market Cap355.01M Forward P/E- EPS next Y-0.55 Insider Trans-23.59% Shs Float11.68M Perf Month-2.87%
Income-39.83M PEG- EPS next Q-0.29 Inst Own65.41% Short Float1.12% Perf Quarter10.45%
Sales21.61M P/S16.43 EPS this Y73.27% Inst Trans0.26% Short Ratio4.79 Perf Half Y25.65%
Book/sh7.21 P/B4.18 EPS next Y49.07% ROA-17.25% Short Interest0.13M Perf Year85.42%
Cash/sh12.13 P/C2.48 EPS next 5Y19.00% ROE-31.41% 52W Range14.77 - 35.00 Perf YTD62.86%
Dividend Est.- P/FCF- EPS past 5Y-20.43% ROI-20.58% 52W High-13.91% Beta0.87
Dividend TTM- Quick Ratio7.52 Sales past 5Y46.25% Gross Margin98.92% 52W Low103.99% ATR (14)1.61
Dividend Ex-Date- Current Ratio7.52 EPS Y/Y TTM-22.66% Oper. Margin-71.30% RSI (14)46.01 Volatility5.23% 5.20%
Employees13 Debt/Eq1.40 Sales Y/Y TTM389.82% Profit Margin-184.33% Recom1.67 Target Price89.00
Option/ShortYes / Yes LT Debt/Eq1.28 EPS Q/Q-165.10% Payout- Rel Volume1.37 Prev Close31.74
Sales Surprise10.61% EPS Surprise-264.09% Sales Q/Q767.11% EarningsNov 07 BMO Avg Volume27.25K Price30.13
SMA20-3.00% SMA501.71% SMA20012.53% Trades Volume37,426 Change-5.07%
Date Action Analyst Rating Change Price Target Change
Apr-29-24Initiated Leerink Partners Outperform $40
Sep-07-21Downgrade Wedbush Outperform → Neutral $22
Jun-29-21Initiated Aegis Capital Buy $60
Jan-19-21Reiterated H.C. Wainwright Buy $30 → $56
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Dec-02-24 07:30AM
Nov-11-24 12:00PM
Nov-07-24 09:00AM
07:52AM
07:30AM
08:00AM Loading…
Oct-22-24 08:00AM
08:00AM
Sep-23-24 06:30AM
05:30AM
Sep-04-24 07:30AM
Aug-13-24 08:45AM
07:39AM
07:30AM
Jul-18-24 04:08AM
Jun-21-24 07:54AM
07:30AM Loading…
Jun-20-24 07:30AM
Jun-12-24 07:30AM
06:00AM
May-14-24 07:30AM
May-10-24 03:18PM
May-09-24 01:55PM
08:00AM
07:30AM
May-07-24 10:00AM
Apr-30-24 07:30AM
Apr-25-24 07:30AM
Apr-24-24 09:00AM
Apr-03-24 09:00AM
Mar-21-24 07:30AM
Mar-19-24 04:05PM
12:53PM Loading…
Mar-08-24 12:53PM
08:12AM
07:52AM
07:30AM
Feb-28-24 07:30AM
Feb-16-24 08:00AM
Jan-18-24 08:30AM
Jan-11-24 04:05PM
Jan-08-24 07:30AM
Jan-02-24 07:30AM
Dec-20-23 07:30AM
Dec-19-23 07:30AM
Nov-07-23 07:50AM
07:30AM
Oct-31-23 07:30AM
Sep-25-23 07:30AM
Sep-06-23 07:30AM
Aug-31-23 10:43PM
Aug-13-23 10:07AM
Aug-08-23 08:21AM
07:30AM
Jun-23-23 06:14PM
Jun-22-23 07:30AM
Jun-20-23 07:30AM
May-16-23 09:29AM
May-09-23 07:53AM
07:30AM
Apr-26-23 07:30AM
Mar-30-23 07:30AM
Mar-21-23 07:30AM
Mar-10-23 05:36AM
Mar-09-23 07:50AM
07:30AM
Mar-06-23 08:28AM
Feb-28-23 07:30AM
Jan-06-23 07:00PM
Jan-04-23 07:30AM
Dec-22-22 07:30AM
Dec-07-22 07:44AM
Nov-22-22 07:01AM
Nov-06-22 09:24AM
Nov-03-22 09:05AM
07:30AM
Sep-27-22 08:30AM
Sep-21-22 07:30AM
Sep-07-22 07:30AM
Sep-01-22 06:20AM
Aug-11-22 06:22AM
Aug-04-22 10:45AM
07:30AM
Jun-30-22 07:33AM
Jun-20-22 07:30AM
Jun-02-22 01:00AM
May-30-22 07:06AM
May-17-22 04:05PM
May-07-22 08:27AM
May-05-22 08:55AM
07:30AM
May-03-22 08:15AM
Apr-20-22 08:24AM
Mar-21-22 07:30AM
Mar-15-22 06:21AM
Mar-10-22 09:43AM
07:30AM
Mar-08-22 07:30AM
Mar-01-22 07:30AM
Feb-17-22 07:30AM
Jan-21-22 10:21AM
Dec-23-21 07:30AM
Dec-21-21 07:30AM
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BURNS THOMAS M.SVP, Finance & CFONov 11 '24Option Exercise0.0017,773024,328Nov 13 06:55 PM
BURNS THOMAS M.SVP, Finance & CFONov 13 '24Sale29.949,775292,66414,553Nov 13 06:55 PM
Hughes OwenChief Executive OfficerNov 11 '24Option Exercise0.0053,360056,860Nov 13 06:55 PM
Hughes OwenChief Executive OfficerNov 13 '24Sale29.9521,881655,33634,979Nov 13 06:55 PM